Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Buy
72
SLS Quote, Financials, Valuation and Earnings
Last price:
$2.78
Seasonality move
:
1.34%
Day range:
$2.41 - $2.66
52-week range:
$0.85 - $2.66
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
8.24x
Volume:
8.9M
Avg. volume:
5M
1-year change:
197.3%
Market cap:
$376M
Revenue:
--
EPS (TTM):
-$0.29
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SLS
SELLAS Life Sciences Group, Inc.
|
-- | -$0.08 | -- | -19.51% | $6.83 |
|
ADMA
ADMA Biologics, Inc.
|
$130.5M | $0.16 | 18.97% | -56.04% | $25.67 |
|
GERN
Geron Corp.
|
$53.3M | -$0.04 | 7.03% | -8.38% | $3.60 |
|
GTBP
GT Biopharma, Inc.
|
-- | -- | -- | -- | $8.00 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SLS
SELLAS Life Sciences Group, Inc.
|
$2.64 | $6.83 | $376M | -- | $0.00 | 0% | -- |
|
ADMA
ADMA Biologics, Inc.
|
$19.88 | $25.67 | $4.7B | 23.35x | $0.00 | 0% | 10.01x |
|
GERN
Geron Corp.
|
$1.35 | $3.60 | $861.8M | -- | $0.00 | 0% | 4.90x |
|
GTBP
GT Biopharma, Inc.
|
$0.77 | $8.00 | $8.2M | -- | $0.00 | 0% | 59.35x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$5.43 | $0.85 | $684.2M | 9.12x | $0.80 | 0% | 10.55x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SLS
SELLAS Life Sciences Group, Inc.
|
1.3% | 2.404 | 0.3% | 7.50x |
|
ADMA
ADMA Biologics, Inc.
|
16.16% | -2.565 | 2.38% | 3.53x |
|
GERN
Geron Corp.
|
50.25% | 1.700 | 28.73% | 4.76x |
|
GTBP
GT Biopharma, Inc.
|
-- | -0.510 | 4.06% | 1.98x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SLS
SELLAS Life Sciences Group, Inc.
|
-- | -$7.1M | -100.8% | -103.86% | -- | -$7.1M |
|
ADMA
ADMA Biologics, Inc.
|
$75.6M | $51M | 47.04% | 58.71% | 38.01% | -$1.1M |
|
GERN
Geron Corp.
|
$45.9M | -$13.9M | -16.45% | -29.65% | -29.41% | -$13.5M |
|
GTBP
GT Biopharma, Inc.
|
-- | -$3.4M | -626.24% | -626.24% | -- | -$3.7M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
SELLAS Life Sciences Group, Inc. vs. Competitors
-
Which has Higher Returns SLS or ADMA?
ADMA Biologics, Inc. has a net margin of -- compared to SELLAS Life Sciences Group, Inc.'s net margin of 27.14%. SELLAS Life Sciences Group, Inc.'s return on equity of -103.86% beat ADMA Biologics, Inc.'s return on equity of 58.71%.
Company Gross Margin Earnings Per Share Invested Capital SLSSELLAS Life Sciences Group, Inc.-- -$0.06 $46.2M ADMAADMA Biologics, Inc.56.32% $0.15 $514.3M -
What do Analysts Say About SLS or ADMA?
SELLAS Life Sciences Group, Inc. has a consensus price target of $6.83, signalling upside risk potential of 158.84%. On the other hand ADMA Biologics, Inc. has an analysts' consensus of $25.67 which suggests that it could grow by 29.11%. Given that SELLAS Life Sciences Group, Inc. has higher upside potential than ADMA Biologics, Inc., analysts believe SELLAS Life Sciences Group, Inc. is more attractive than ADMA Biologics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SLSSELLAS Life Sciences Group, Inc.2 0 0 ADMAADMA Biologics, Inc.3 0 0 -
Is SLS or ADMA More Risky?
SELLAS Life Sciences Group, Inc. has a beta of 2.508, which suggesting that the stock is 150.829% more volatile than S&P 500. In comparison ADMA Biologics, Inc. has a beta of 0.433, suggesting its less volatile than the S&P 500 by 56.749%.
-
Which is a Better Dividend Stock SLS or ADMA?
SELLAS Life Sciences Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SELLAS Life Sciences Group, Inc. pays -- of its earnings as a dividend. ADMA Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLS or ADMA?
SELLAS Life Sciences Group, Inc. quarterly revenues are --, which are smaller than ADMA Biologics, Inc. quarterly revenues of $134.2M. SELLAS Life Sciences Group, Inc.'s net income of -$6.8M is lower than ADMA Biologics, Inc.'s net income of $36.4M. Notably, SELLAS Life Sciences Group, Inc.'s price-to-earnings ratio is -- while ADMA Biologics, Inc.'s PE ratio is 23.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SELLAS Life Sciences Group, Inc. is -- versus 10.01x for ADMA Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLSSELLAS Life Sciences Group, Inc.-- -- -- -$6.8M ADMAADMA Biologics, Inc.10.01x 23.35x $134.2M $36.4M
-
Which has Higher Returns SLS or GERN?
Geron Corp. has a net margin of -- compared to SELLAS Life Sciences Group, Inc.'s net margin of -39.02%. SELLAS Life Sciences Group, Inc.'s return on equity of -103.86% beat Geron Corp.'s return on equity of -29.65%.
Company Gross Margin Earnings Per Share Invested Capital SLSSELLAS Life Sciences Group, Inc.-- -$0.06 $46.2M GERNGeron Corp.97.13% -$0.03 $500M -
What do Analysts Say About SLS or GERN?
SELLAS Life Sciences Group, Inc. has a consensus price target of $6.83, signalling upside risk potential of 158.84%. On the other hand Geron Corp. has an analysts' consensus of $3.60 which suggests that it could grow by 166.67%. Given that Geron Corp. has higher upside potential than SELLAS Life Sciences Group, Inc., analysts believe Geron Corp. is more attractive than SELLAS Life Sciences Group, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SLSSELLAS Life Sciences Group, Inc.2 0 0 GERNGeron Corp.3 1 1 -
Is SLS or GERN More Risky?
SELLAS Life Sciences Group, Inc. has a beta of 2.508, which suggesting that the stock is 150.829% more volatile than S&P 500. In comparison Geron Corp. has a beta of 0.567, suggesting its less volatile than the S&P 500 by 43.26%.
-
Which is a Better Dividend Stock SLS or GERN?
SELLAS Life Sciences Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Geron Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SELLAS Life Sciences Group, Inc. pays -- of its earnings as a dividend. Geron Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLS or GERN?
SELLAS Life Sciences Group, Inc. quarterly revenues are --, which are smaller than Geron Corp. quarterly revenues of $47.2M. SELLAS Life Sciences Group, Inc.'s net income of -$6.8M is higher than Geron Corp.'s net income of -$18.4M. Notably, SELLAS Life Sciences Group, Inc.'s price-to-earnings ratio is -- while Geron Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SELLAS Life Sciences Group, Inc. is -- versus 4.90x for Geron Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLSSELLAS Life Sciences Group, Inc.-- -- -- -$6.8M GERNGeron Corp.4.90x -- $47.2M -$18.4M
-
Which has Higher Returns SLS or GTBP?
GT Biopharma, Inc. has a net margin of -- compared to SELLAS Life Sciences Group, Inc.'s net margin of --. SELLAS Life Sciences Group, Inc.'s return on equity of -103.86% beat GT Biopharma, Inc.'s return on equity of -626.24%.
Company Gross Margin Earnings Per Share Invested Capital SLSSELLAS Life Sciences Group, Inc.-- -$0.06 $46.2M GTBPGT Biopharma, Inc.-- -$0.83 $3M -
What do Analysts Say About SLS or GTBP?
SELLAS Life Sciences Group, Inc. has a consensus price target of $6.83, signalling upside risk potential of 158.84%. On the other hand GT Biopharma, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 933.73%. Given that GT Biopharma, Inc. has higher upside potential than SELLAS Life Sciences Group, Inc., analysts believe GT Biopharma, Inc. is more attractive than SELLAS Life Sciences Group, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SLSSELLAS Life Sciences Group, Inc.2 0 0 GTBPGT Biopharma, Inc.1 0 0 -
Is SLS or GTBP More Risky?
SELLAS Life Sciences Group, Inc. has a beta of 2.508, which suggesting that the stock is 150.829% more volatile than S&P 500. In comparison GT Biopharma, Inc. has a beta of 1.524, suggesting its more volatile than the S&P 500 by 52.367%.
-
Which is a Better Dividend Stock SLS or GTBP?
SELLAS Life Sciences Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GT Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SELLAS Life Sciences Group, Inc. pays -- of its earnings as a dividend. GT Biopharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLS or GTBP?
SELLAS Life Sciences Group, Inc. quarterly revenues are --, which are smaller than GT Biopharma, Inc. quarterly revenues of --. SELLAS Life Sciences Group, Inc.'s net income of -$6.8M is lower than GT Biopharma, Inc.'s net income of -$3.1M. Notably, SELLAS Life Sciences Group, Inc.'s price-to-earnings ratio is -- while GT Biopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SELLAS Life Sciences Group, Inc. is -- versus 59.35x for GT Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLSSELLAS Life Sciences Group, Inc.-- -- -- -$6.8M GTBPGT Biopharma, Inc.59.35x -- -- -$3.1M
-
Which has Higher Returns SLS or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to SELLAS Life Sciences Group, Inc.'s net margin of -255.85%. SELLAS Life Sciences Group, Inc.'s return on equity of -103.86% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital SLSSELLAS Life Sciences Group, Inc.-- -$0.06 $46.2M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About SLS or NBY?
SELLAS Life Sciences Group, Inc. has a consensus price target of $6.83, signalling upside risk potential of 158.84%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -84.35%. Given that SELLAS Life Sciences Group, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe SELLAS Life Sciences Group, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SLSSELLAS Life Sciences Group, Inc.2 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is SLS or NBY More Risky?
SELLAS Life Sciences Group, Inc. has a beta of 2.508, which suggesting that the stock is 150.829% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock SLS or NBY?
SELLAS Life Sciences Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. SELLAS Life Sciences Group, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLS or NBY?
SELLAS Life Sciences Group, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. SELLAS Life Sciences Group, Inc.'s net income of -$6.8M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, SELLAS Life Sciences Group, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 9.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SELLAS Life Sciences Group, Inc. is -- versus 10.55x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLSSELLAS Life Sciences Group, Inc.-- -- -- -$6.8M NBYNovaBay Pharmaceuticals, Inc.10.55x 9.12x $521K -$1.3M
-
Which has Higher Returns SLS or PTN?
Palatin Technologies has a net margin of -- compared to SELLAS Life Sciences Group, Inc.'s net margin of --. SELLAS Life Sciences Group, Inc.'s return on equity of -103.86% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SLSSELLAS Life Sciences Group, Inc.-- -$0.06 $46.2M PTNPalatin Technologies-- -- -- -
What do Analysts Say About SLS or PTN?
SELLAS Life Sciences Group, Inc. has a consensus price target of $6.83, signalling upside risk potential of 158.84%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than SELLAS Life Sciences Group, Inc., analysts believe Palatin Technologies is more attractive than SELLAS Life Sciences Group, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SLSSELLAS Life Sciences Group, Inc.2 0 0 PTNPalatin Technologies0 0 0 -
Is SLS or PTN More Risky?
SELLAS Life Sciences Group, Inc. has a beta of 2.508, which suggesting that the stock is 150.829% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock SLS or PTN?
SELLAS Life Sciences Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SELLAS Life Sciences Group, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLS or PTN?
SELLAS Life Sciences Group, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. SELLAS Life Sciences Group, Inc.'s net income of -$6.8M is higher than Palatin Technologies's net income of --. Notably, SELLAS Life Sciences Group, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SELLAS Life Sciences Group, Inc. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLSSELLAS Life Sciences Group, Inc.-- -- -- -$6.8M PTNPalatin Technologies-- -- -- --
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 23
Applied Optoelectronics, Inc. [AAOI] is up 3.49% over the past day.
Buy
52
ABVX alert for Dec 23
Abivax SA [ABVX] is up 1.21% over the past day.
Buy
69
QBTS alert for Dec 23
D-Wave Quantum, Inc. [QBTS] is down 6.43% over the past day.
